Pfizer, PSI partner to treat hypertension in Southeast Asia

Pfizer Inc. and nonprofit Population Services International (PSI) recently announced a $1 million collaboration that will make it easier for people with hypertension in Myanmar and Vietnam to access medicine and treatment.

“Pfizer has partnered with PSI for many years based on our shared vision of making a meaningful contribution to improving global health and ensuring access to quality healthcare, especially in underserved communities around the world,” Pfizer Essential Health Group President John Young said. “Through this partnership we are helping to improve the diagnosis and treatment of hypertension, which ultimately can aid in preventing severe illness and saving lives.”

The collaboration, dubbed Health Communities, will work to develop sustainable and scalable treatment models and try to find the best ways to eliminate barriers that prevent many of the 250,000 adults in the two countries with hypertension1,2 from getting treatment.

“PSI's partnership with Pfizer is a great example of the impact that can be achieved when values are shared between organizations that are committed to learning and improving the health of people in low resource settings,” PSI President and CEO Karl Hofmann said. “We are excited to work with Pfizer to better understand hypertension management in Asia, investigate the needs of our joint consumers, and ensure that we are building long term-programs to provide basic health for all.”